Page 78 - Memoria FEHH - SEHH 2017
P. 78

  GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS (GESMD)
MEMORIA ANUAL 2017
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• García-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcárcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤30% blasts. Leukemia. 2017;31(12):2799-806.
• Gerds AT, Woo Ahn K, Hu ZH, Abdel-Azim H, Akpek G, Aljurf M, Ballen KK, Beitinjaneh A, Bacher U, Cahn JY, Chha- bra S, Cutler C, Daly A, DeFilipp Z, Gale RP, Gergis U, Grunwald MR, Hale GA, Hamilton BK, Jagasia M, Kamble RT, Kindwall-Keller T, Nishihori T, Olsson RF, Ramanathan M, Saad AA, Solh M, Ustun C, Valcárcel D, Warlick E, Wirk BM, Kalaycio M, Alyea E, Popat U, Sobecks R, Saber W. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2017;23(6):971-9.
• Ivars D, Orero MT, Javier K, Díaz-Vico L, García-Giménez JL, Mena S, Tormos C, Egea M, Pérez PL, Arrizabalaga B, Ruiz MA, Yagüe N, Tormo M, Sancho-Tello R, Gomes A, Algueró C, O’Connor JE, Sáez GT, Carbonell F, Collado R. Oxidative imbalance in low/intermediate-1-risk myelodysplastic syndrome patients: the influence of iron overload. Clin Biochem. 2017;50(16-17):911-7.
• Janusz K, Del Rey M, Abáigar M, Collado R, Ivars D, Hernández-Sánchez M, Valiente A, Robledo C, Benito R, Díez-Campelo M, Ramos F, Kohlmann A, Cañizo CD, Hernández-Rivas JM. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts. Leuk Res. 2017;56:82-7.
• Montoro J, Robledo C, Zamora L, Valcárcel D, Ramos F. Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. Ann Hematol. 2017;96(2):317-8.
• Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnán M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nom- dedeu B, Sanz G; Spanish MDS Group. Excess mortality in the myelodysplastic syndromes. Am J Hematol. 2017;92(2):149-54.
• Nomdedeu M, Pereira A, Calvo X, Colomer J, Solé F, Arias A, Gómez C, Luño E, Cervera J, Arnán M, Pomares H, Ramos F, Oiartzabal I, Espinet B, Pedro C, Arrizabalaga B, Blanco ML, Tormo M, Hernández-Rivas JM, Díez-Campelo M, Ortega M, Valcárcel D, Cedena MT, Collado R, Grau J, Granada I, Sanz G, Campo E, Esteve J, Costa D; Spanish MDS Group. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leuk Res. 2017;63:85-9.
• Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcárcel D. Donor lymphocyte infusions in AML and MDS: Enhanc- ing the graft-versus-leukemia effect. Exp Hematol. 2017;48:1-11.
• Palau A, Mallo M, Palomo L, Rodríguez-Hernández I, Diesch J, Campos D, Granada I, Juncà J, Drexler HG, Solé F, Buschbeck M. Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. Genes Chromosomes Can- cer. 2017;56(3):243-52.
• Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, Haro N, Mallo M, Xicoy B, Za- mora L, Solé F. Inspecting targeted deep sequencing of whole genome amplified DNA versus fresh DNA for somatic mutation detection: A genetic study in myelodysplastic syndrome patients. Biopreserv Biobank. 2017;15(4):360-5.
• Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J,
78
 


















































































   76   77   78   79   80